Acetyl-CoA

Ensovi Leverages Ginkgo Enzyme Services to Optimize Cell-Free Carbon Fixation Process for Biomanufacturing

Retrieved on: 
Thursday, September 28, 2023
DNA, Partnership, Commercialization, Senior, Carbon dioxide, Enzyme, Recycling, Synthetic biology, NYSE, Chemical industry, Ginkgo Bioworks, Ginkgo, Engineering, Acetyl-CoA, Organic, CO2, Fine chemical

Under the terms of the agreement, Ginkgo will support the discovery and development of enzymes needed to bring Ensovi's cell-free biomanufacturing platform to market.

Key Points: 
  • Under the terms of the agreement, Ginkgo will support the discovery and development of enzymes needed to bring Ensovi's cell-free biomanufacturing platform to market.
  • Ginkgo Enzyme Services offers partners end-to-end support for the discovery, engineering, optimization, and scale-up of enzymes for diverse applications.
  • Through the partnership, Ginkgo will leverage its suite of services, including metagenomic enzyme discovery, as well as enzyme optimization for function and stability to support Ensovi's applications.
  • To learn more about Ginkgo Enzyme Services, please visit ginkgobioworks.com/enzyme-services/ .

OrsoBio Announces First Patient Dosed in Phase 2 Clinical Trial of the ACC2 Inhibitor TLC-3595, a Potential Treatment for Type 2 Diabetes

Retrieved on: 
Monday, March 20, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Glycated hemoglobin, Insulin resistance, Yale School of Medicine, FRCP, Obesity, NASH, Glucose, Cardiovascular disease, OGTT, Cancer, Type 2 diabetes, Lipid, Liver, Yale school, Biomarker, Doctor of Philosophy, MACE, MACP, FAO, DSM-IV codes, Kidney, Acetyl-CoA, MRS, MD, Patient, LDL, Overweight, Fatty liver disease, Poster, Prediabetes, Abstract, Safety, Pharmaceutical industry, Medicine

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced that the first patient has been dosed in a Phase 2a clinical trial evaluating TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2).

Key Points: 
  • OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced that the first patient has been dosed in a Phase 2a clinical trial evaluating TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2).
  • The trial aims to demonstrate the safety and insulin-sensitizing effects of TLC-3595 in patients with insulin resistance, including those with type 2 diabetes on approved glucose-lowering therapies.
  • Proof-of-concept data supporting the safety and efficacy of TLC-3595 will be available by the end of 2023.
  • The study will enroll 50 overweight or obese subjects with insulin resistance, including type 2 diabetes treated with glucose-lowering therapies.

Translational Research Describes an Epigenetic Approach for Regulating Fear-Memory

Retrieved on: 
Monday, August 22, 2022
Memorial Day, Nature, University, Icahn School of Medicine at Mount Sinai, Ben-Gurion University of the Negev, CEO, Perelman School of Medicine at the University of Pennsylvania, UC, Wood, Research, Neuron, Gene, Time, Doctor of Philosophy, Penn, Psychiatry, Memory, Acetyl-CoA, Mouse, Anxiety, Acetyl group, ACSS2, Mount Sinai, National, RATS, Addiction, Alzheimer's disease, Animal, University of Pennsylvania, Post-traumatic stress disorder, National academy, Fear, Lists of diseases, Yale University, Therapy, Adult, Trauma, Mews, University of California, Irvine, Intellectual property, Urine, Memory consolidation, Pharmaceutical industry, Vaccine, Meat, PTSD, PNAS

PHILADELPHIA, Aug. 22, 2022 /PRNewswire/ -- EpiVario, Inc., an emerging biotech company developing novel therapeutics for memory-related psychiatric disorders, today highlighted preclinical research findings that could lead to a treatment approach for PTSD. Published in Proceedings of the National Academy of Sciences (PNAS), and co-authored by the academic co-founders of EpiVario, the study demonstrates that fear memories can be controlled through the enzyme acetyl-CoA synthetase 2 (ACSS2). The team also confirmed that a small molecule inhibitor against ACSS2 can block the epigenetic process required for the consolidation of stress and fear memories. 

Key Points: 
  • The team also confirmed that a small molecule inhibitor against ACSS2 can block the epigenetic process required for the consolidation of stress and fear memories.
  • Investigational small molecule compounds were provided by EpiVario, which is developing ACSS2 inhibitors as a therapeutic for memory related neuropsychiatric disorders.
  • "These new results are exciting, as they validate our earlier discovery that ACSS2 is critical for activating genes during the creation of fear memories.
  • These memories are attenuated via epigenetic regulation through the target enzyme acetyl-coA synthetase 2 (ACSS2), which regulates consolidation of fear and drug-craving memories.

Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Retrieved on: 
Thursday, May 26, 2022
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Acetyl-CoA carboxylase, Disease, Food, Epidemiology, U.S. Securities and Exchange Commission, Lipid metabolism, Review, Liver, Acci, Non-alcoholic fatty liver disease, YouTube, EMA, Twitter, WP, Prevalence, Kidney, Epidemic, Clinical trial, COVID-19, Inc., Fatty liver disease, Research, Facebook, Type 2, ACC, Fast Track, NYSE, Digestive, Inflammation, Hospital, NASH, Enzyme, Science, Vaccine, FDA, Gastroenterology, Fibrosis, Internal medicine, Ageing, LinkedIn, PFE, Senior, Risk, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Obesity, Liver disease, Safety, National Institute of Diabetes and Digestive and Kidney Diseases, Cirrhosis, NAFLD, Acetyl-CoA, Rusyns, News, Pharmaceutical industry, Dietary supplement, Pfizer, Nature Medicine, Diabetes

Receiving Fast Track designation from the FDA reinforces Pfizers belief in ervogastat/clesacostat as a potential treatment for NASH, a serious, progressive liver disease with no currently approved therapies, said James Rusnak, M.D., Ph.D., Senior Vice President and Chief Development Officer, Internal Medicine and Hospital, Pfizer.

Key Points: 
  • Receiving Fast Track designation from the FDA reinforces Pfizers belief in ervogastat/clesacostat as a potential treatment for NASH, a serious, progressive liver disease with no currently approved therapies, said James Rusnak, M.D., Ph.D., Senior Vice President and Chief Development Officer, Internal Medicine and Hospital, Pfizer.
  • The results of this study, which also includes arms investigating ervogastat as monotherapy, will inform a potential Phase 3 development program.
  • Diacylglycerol O-acyltransferase 2 (DGAT2) and acetyl-CoA carboxylase (ACC) are two key enzymes that regulate lipid metabolism.
  • At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

Nimbus Therapeutics and Schrödinger Extend Longstanding Collaboration to Discover Novel Therapeutics for Select Targets

Retrieved on: 
Thursday, August 12, 2021
Biotechnology, Pharmaceutical, Health, Medical Supplies, Protein, MBA, Therapy, Drug discovery, Acetyl-CoA carboxylase, Acetyl-CoA, Machine learning, Industry, ACC, TYK2, Pathology, Pharmaceutical industry

Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the extension of its collaboration with Schrdinger, Inc. to discover and design small molecule therapeutics for a number of high-value targets using cutting-edge structure-based drug design approaches.

Key Points: 
  • Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the extension of its collaboration with Schrdinger, Inc. to discover and design small molecule therapeutics for a number of high-value targets using cutting-edge structure-based drug design approaches.
  • The agreement extends the collaboration between the two companies, which began in 2009, to advance the usage of computational methods in drug discovery.
  • Nimbus collaboration with Schrdinger over the past 12 years has been groundbreaking, deploying computational horsepower at an unprecedented scale in the industry, said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus.
  • Schrdingers deep computational capabilities, paired with Nimbus demonstrated expertise in structural biology, small molecule drug discovery and clinical development, provides fertile ground for designing breakthrough medicines over the next decade.

Global Acetyl-Coa Carboxylase Inhibitors Pipeline Insight Report 2021 Featuring Emerging Drugs Such as Firsocostat: Gilead Sciences & Clesacostat: Pfizer - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 13, 2021
Health, Pharmaceutical, Enzymes, Metabolism, Acetyl-CoA carboxylase, Acetyl-CoA, (acetyl-CoA carboxylase) kinase, Metabolic pathways, (acetyl-CoA carboxylase)-phosphatase

b'The "Acetyl-Coa Carboxylase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Acetyl-CoA carboxylase inhibitors - Pipeline Insight, 2021 report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Acetyl-CoA carboxylase inhibitors pipeline landscape.\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products.

Key Points: 
  • b'The "Acetyl-Coa Carboxylase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Acetyl-CoA carboxylase inhibitors - Pipeline Insight, 2021 report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Acetyl-CoA carboxylase inhibitors pipeline landscape.\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products.
  • It further highlights the inactive pipeline products in this space.\nThis segment of the Acetyl-CoA carboxylase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery.
  • 3+ key companies which are developing the Acetyl-CoA carboxylase inhibitors.
  • The companies which have their Acetyl-CoA carboxylase inhibitors drug candidates in the most advanced stage, i.e.

EpiVario Secures Exclusive Worldwide License for Novel Technologies and Drugs for Memory-Related Psychiatric Diseases from University of Pennsylvania

Retrieved on: 
Wednesday, January 16, 2019
Acetyl-CoA, Cholinergics, Metabolism, License, Acetyl—CoA synthetase, Patent, University of Pennsylvania, Penn, PENNSYLVANIA

The license agreement, executed by EpiVario and the Trustees of the University of Pennsylvania (Penn), covers patents related to the acetyl-CoA synthetase (ACSS2) gene and its role in memory-related psychiatric conditions.

Key Points: 
  • The license agreement, executed by EpiVario and the Trustees of the University of Pennsylvania (Penn), covers patents related to the acetyl-CoA synthetase (ACSS2) gene and its role in memory-related psychiatric conditions.
  • EpiVario and Penn also executed a sponsored research agreement, which funds the lab of Dr. Shelley Berger, the Daniel S. Och University Professor at the University of Pennsylvania and one of EpiVario's co-founders.
  • Through this agreement, EpiVario will have access to additional understanding of ACSS2 and potentially other modulators of its activity.
  • "Securing this exclusive license was a key element in our strategy to be the first to bring this treatment to market with strong patent protection," said Thomas Kim, CEO of EpiVario.